UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED: ~~March 31,~~June 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-35280

VERICEL CORPORATION

(Exact name of registrant as specified in its charter)


Michigan						94-3096597
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

64 Sidney Street

Cambridge, MA 02139

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (617) 588-5555

Securities registered pursuant to Section 12(b) of the Act:


Title of Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock (No par value)	VCEL	NASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

As of ~~April~~July 29, 2022, ~~47,119,902~~47,177,974 shares of Common Stock, no par value per share, were outstanding.

Table of Contents

VERICEL CORPORATION

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS


		Page
	PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited):	3
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Operations	4
	Condensed Consolidated Statements of Comprehensive Loss	5
	Condensed Consolidated Statements of ~~Shareholders~~’Shareholders’ Equity	6
	Condensed Consolidated Statements of Cash Flows	7
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2122
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2629
Item 4.	Controls and Procedures	2629
	PART II — OTHER INFORMATION
Item 1.	Legal Proceedings	2629
Item 1A.	Risk Factors	2629

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2730
Item 3.	Defaults Upon Senior Securities	2730
Item 4.	Mine Safety Disclosures	2730
Item 5.	Other Information	2730
Item 6.	Exhibits	2831
Exhibit Index		2831
Signatures		3033

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

VERICEL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, amounts in thousands)


		March 31,		December 31,			June 30,		December 31,
		2022		2021			2022		2021
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	55,659	$	68,330	Cash and cash equivalents	$	56,054	$	68,330
Short-term investments	Short-term investments	44,888		35,068		Short-term investments	44,638		35,068
Accounts receivable (net of allowance for doubtful accounts of $40 and $40, respectively)	Accounts receivable (net of allowance for doubtful accounts of $40 and $40, respectively)	31,855		37,437		Accounts receivable (net of allowance for doubtful accounts of $40 and $40, respectively)	33,664		37,437
Inventory	Inventory	14,385		13,381		Inventory	15,929		13,381
Other current assets	Other current assets	5,093		4,246		Other current assets	4,809		4,246
Total current assets	Total current assets	151,880		158,462		Total current assets	155,094		158,462
Property and equipment, net	Property and equipment, net	14,451		13,308		Property and equipment, net	15,919		13,308
Restricted cash	Restricted cash	6,184		211		Restricted cash	6,184		211
Right-of-use assets	Right-of-use assets	44,653		45,720		Right-of-use assets	43,583		45,720
Long-term investments	Long-term investments	22,803		25,687		Long-term investments	23,718		25,687
Other long-term assets	Other long-term assets	317		317		Other long-term assets	317		317
Total assets	Total assets	$	240,288	$	243,705	Total assets	$	244,815	$	243,705
LIABILITIES AND SHAREHOLDERS’ EQUITY	LIABILITIES AND SHAREHOLDERS’ EQUITY					LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	7,750	$	9,016	Accounts payable	$	9,684	$	9,016
Accrued expenses	Accrued expenses	10,793		14,045		Accrued expenses	12,133		14,045
Current portion of operating lease liabilities	Current portion of operating lease liabilities	3,147		2,950		Current portion of operating lease liabilities	3,156		2,950
Other current liabilities	Other current liabilities	41		41		Other current liabilities	41		41
Total current liabilities	Total current liabilities	21,731		26,052		Total current liabilities	25,014		26,052
Operating lease liabilities	Operating lease liabilities	46,053		47,147		Operating lease liabilities	44,964		47,147
Other long-term liabilities	Other long-term liabilities	19		44		Other long-term liabilities	21		44
Total liabilities	Total liabilities	67,803		73,243		Total liabilities	69,999		73,243
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES	0		0		COMMITMENTS AND CONTINGENCIES	0		0
Shareholders’ equity:	Shareholders’ equity:					Shareholders’ equity:
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,081 and 46,880, respectively		563,475		553,902
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,141 and 46,880, respectively						Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,141 and 46,880, respectively	575,011		553,902
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(613)		(154)		Accumulated other comprehensive loss	(855)		(154)
Accumulated deficit	Accumulated deficit	(390,377)		(383,286)		Accumulated deficit	(399,340)		(383,286)
Total shareholders’ equity	Total shareholders’ equity	172,485		170,462		Total shareholders’ equity	174,816		170,462
Total liabilities and shareholders’ equity	Total liabilities and shareholders’ equity	$	240,288	$	243,705	Total liabilities and shareholders’ equity	$	244,815	$	243,705

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

Table of Contents

VERICEL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except per share amounts)


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
		2022		2021				2022		2021		2022		2021
Product sales, net	Product sales, net	$	35,852	$	33,627		Product sales, net	$	36,826	$	38,680	$	72,678	$	72,307
Other revenue	Other revenue	222		941			Other revenue	220		839		442		1,780
Total revenue	Total revenue	36,074		34,568			Total revenue	37,046		39,519		73,120		74,087
Cost of product sales	Cost of product sales	12,622		11,583			Cost of product sales	14,192		12,609		26,814		24,192
Gross profit	Gross profit	23,452		22,985			Gross profit	22,854		26,910		46,306		49,895
Research and development	Research and development	4,860		3,630			Research and development	4,792		4,449		9,652		8,079
Selling, general and administrative	Selling, general and administrative	25,865		22,660			Selling, general and administrative	27,144		26,190		53,009		48,850
Total operating expenses	Total operating expenses	30,725		26,290			Total operating expenses	31,936		30,639		62,661		56,929
Loss from operations	Loss from operations	(7,273)		(3,305)			Loss from operations	(9,082)		(3,729)		(16,355)		(7,034)
Other income (expense):	Other income (expense):						Other income (expense):
Interest income	Interest income	88		76			Interest income	148		43		236		119
Interest expense	Interest expense	(18)		(1)			Interest expense	(20)		(1)		(38)		(2)
Other income		112		84
Other income (expense)							Other income (expense)	(9)		(27)		103		57
Total other income	Total other income	182		159			Total other income	119		15		301		174
Loss before income taxes	Loss before income taxes	(7,091)		(3,146)			Loss before income taxes	(8,963)		(3,714)		(16,054)		(6,860)
Income tax expense	Income tax expense	—		143			Income tax expense	—		72		—		215
Net loss	Net loss	$	(7,091)	$	(3,289)		Net loss	$	(8,963)	$	(3,786)	$	(16,054)	$	(7,075)
Net loss per common share:	Net loss per common share:						Net loss per common share:
Basic	Basic	$	(0.15)	$	(0.07)		Basic	$	(0.19)	$	(0.08)	$	(0.34)	$	(0.15)
Diluted	Diluted	$	(0.15)	$	(0.07)		Diluted	$	(0.19)	$	(0.08)	$	(0.34)	$	(0.15)
Weighted-average common shares outstanding:	Weighted-average common shares outstanding:						Weighted-average common shares outstanding:
Basic	Basic	46,985		45,984			Basic	47,117		46,403		47,052		46,195
Diluted	Diluted	46,985		45,984			Diluted	47,117		46,403		47,052		46,195

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

Table of Contents

VERICEL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited, amounts in thousands)


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
		2022		2021				2022		2021		2022		2021
Net loss	Net loss	$	(7,091)	$	(3,289)		Net loss	$	(8,963)	$	(3,786)	$	(16,054)	$	(7,075)
Other comprehensive loss:	Other comprehensive loss:						Other comprehensive loss:
Unrealized loss on investments		(459)		(61)
Unrealized (loss) gain on investments							Unrealized (loss) gain on investments	(242)		24		(701)		(37)
Comprehensive loss	Comprehensive loss	$	(7,550)	$	(3,350)		Comprehensive loss	$	(9,205)	$	(3,762)	$	(16,755)	$	(7,112)

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

Table of Contents

VERICEL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited, amounts in thousands)


		Common Stock			Accumulated Other Comprehensive Loss		Accumulated Deficit					Total Shareholders’ Equity			Common Stock								Accumulated Other Comprehensive Loss			Accumulated Deficit			Total Shareholders’ Equity
		Shares	Amount								Shares					Amount
BALANCE, DECEMBER 31, 2021	BALANCE, DECEMBER 31, 2021	46,880	$	553,902	$	(154)			$	(383,286)					$	170,462	BALANCE, DECEMBER 31, 2021	46,880			$	553,902			$	(154)		$	(383,286)		$	170,462
Net loss	Net loss	—	—		—		(7,091)					(7,091)		Net loss	—				—					—			(7,091)			(7,091)
Stock-based compensation expense	Stock-based compensation expense	—	9,531		—		—					9,531		Stock-based compensation expense	—				9,531				—			—			9,531
Stock option exercises	Stock option exercises	125	1,155		—		—					1,155		Stock option exercises	125				1,155				—			—			1,155
Shares issued under the Employee Stock Purchase Plan	Shares issued under the Employee Stock Purchase Plan	9	310		—		—					310		Shares issued under the Employee Stock Purchase Plan	9				310				—			—			310
Issuance of stock for restricted stock unit vesting	Issuance of stock for restricted stock unit vesting	108	—		—		—					—		Issuance of stock for restricted stock unit vesting	108				—				—			—			—
Restricted stock withheld for employee tax remittance	Restricted stock withheld for employee tax remittance	(41)	(1,423)		—		—					(1,423)		Restricted stock withheld for employee tax remittance	(41)				(1,423)				—			—			(1,423)
Unrealized loss on investments	Unrealized loss on investments	—	—		(459)		—					(459)		Unrealized loss on investments	—				—				(459)			—			(459)
BALANCE, MARCH 31, 2022	BALANCE, MARCH 31, 2022	47,081	$	563,475	$	(613)	$	(390,377)				$	172,485	BALANCE, MARCH 31, 2022	47,081				$	563,475			$	(613)		$	(390,377)		$	172,485
Net loss														Net loss	—				—				—			(8,963)			(8,963)
Stock-based compensation expense														Stock-based compensation expense	—				10,808				—			—			10,808
Stock option exercises														Stock option exercises	32				428				—			—			428
Shares issued under the Employee Stock Purchase Plan														Shares issued under the Employee Stock Purchase Plan	10				318				—			—			318
Issuance of stock for restricted stock unit vesting														Issuance of stock for restricted stock unit vesting	19				—				—			—			—
Restricted stock withheld for employee tax remittance														Restricted stock withheld for employee tax remittance	(1)				(18)				—			—			(18)
Unrealized loss on investments														Unrealized loss on investments	—				—				(242)			—			(242)
BALANCE, JUNE 30, 2022														BALANCE, JUNE 30, 2022	47,141				$	575,011			$	(855)		$	(399,340)		$	174,816


		Common Stock			Accumulated Other Comprehensive Income (Loss)				Accumulated Deficit					Total Shareholders’ Equity			Common Stock							Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Shareholders’ Equity
		Shares	Amount										Shares					Amount
BALANCE, DECEMBER 31, 2020	BALANCE, DECEMBER 31, 2020	45,804	$	510,061			$	14			$	(375,815)					$	134,260	BALANCE, DECEMBER 31, 2020	45,804			$		510,061	$	14	$	(375,815)	$	134,260
Net loss	Net loss	—	—		—				(3,289)					(3,289)		Net loss	—				—			—		(3,289)		(3,289)
Stock-based compensation expense	Stock-based compensation expense	—	7,019		—				—					7,019		Stock-based compensation expense	—				7,019			—		—		7,019
Stock option exercises	Stock option exercises	359	3,532		—				—					3,532		Stock option exercises	359				3532			—		—		3,532
Shares issued under the Employee Stock Purchase Plan	Shares issued under the Employee Stock Purchase Plan	14	249		—				—					249		Shares issued under the Employee Stock Purchase Plan	14				249			—		—		249
Issuance of stock for restricted stock unit vesting	Issuance of stock for restricted stock unit vesting	76	—		—				—					—		Issuance of stock for restricted stock unit vesting	76				—			—		—		—
Restricted stock withheld for employee tax remittance	Restricted stock withheld for employee tax remittance	(28)	(1,501)		—				—					(1,501)		Restricted stock withheld for employee tax remittance	(28)				(1,501)			—		—		(1,501)
Unrealized loss on investments	Unrealized loss on investments	—	—		(61)				—					(61)		Unrealized loss on investments	—				—			(61)		—		(61)
BALANCE, MARCH 31, 2021	BALANCE, MARCH 31, 2021	46,225	$	519,360	$	(47)			$	(379,104)				$	140,209	BALANCE, MARCH 31, 2021	46,225				$	519,360		$	(47)	$	(379,104)	$	140,209
Net loss																Net loss	—				—			—		(3,786)		(3,786)
Stock-based compensation expense																Stock-based compensation expense	—				10,866			—		—		10,866
Stock option exercises																Stock option exercises	330				3,531			—		—		3,531
Shares issued under the Employee Stock Purchase Plan																Shares issued under the Employee Stock Purchase Plan	13				309			—		—		309
Issuance of stock for restricted stock unit vesting																Issuance of stock for restricted stock unit vesting	12				—			—		—		—
Restricted stock withheld for employee tax remittance																Restricted stock withheld for employee tax remittance	(1)				(61)			—		—		(61)
Unrealized gain on investments																Unrealized gain on investments	—				—			24		—		24
BALANCE, JUNE 30, 2021																BALANCE, JUNE 30, 2021	46,579				$	534,005		$	(23)	$	(382,890)	$	151,092

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

Table of Contents

VERICEL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, amounts in thousands)


		Three months ended March 31,					Six Months Ended June 30,
		2022		2021			2022		2021
Operating activities:	Operating activities:					Operating activities:
Net loss	Net loss	$	(7,091)	$	(3,289)	Net loss	$	(16,054)	$	(7,075)
Adjustments to reconcile net loss to net cash flows from operating activities:	Adjustments to reconcile net loss to net cash flows from operating activities:					Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization expense	Depreciation and amortization expense	873		811		Depreciation and amortization expense	1,928		1,506
Stock-based compensation expense	Stock-based compensation expense	9,531		7,019		Stock-based compensation expense	20,339		17,885
Amortization of premiums and discounts on marketable securities	Amortization of premiums and discounts on marketable securities	194		273		Amortization of premiums and discounts on marketable securities	302		505
Non-cash lease cost	Non-cash lease cost	1,076		1,171		Non-cash lease cost	2,155		2,325
Other	Other	4		(20)		Other	16		5
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Inventory	Inventory	(1,004)		(966)		Inventory	(2,548)		(3,603)
Accounts receivable	Accounts receivable	5,582		5,382		Accounts receivable	3,773		2,772
Other current assets	Other current assets	(847)		(320)		Other current assets	(563)		1,039
Accounts payable	Accounts payable	(219)		2,174		Accounts payable	1,152		1,356
Accrued expenses	Accrued expenses	(3,734)		(1,328)		Accrued expenses	(1,912)		(216)
Operating lease liabilities	Operating lease liabilities	(897)		(821)		Operating lease liabilities	(1,977)		(1,644)

Net cash provided by operating activities	Net cash provided by operating activities	3,468		10,086		Net cash provided by operating activities	6,611		14,855
Investing activities:	Investing activities:					Investing activities:
Purchases of investments	Purchases of investments	(12,629)		(10,426)		Purchases of investments	(34,948)		(30,951)
Sales and maturities of investments	Sales and maturities of investments	5,041		24,955		Sales and maturities of investments	26,344		32,655
Expenditures for property and equipment	Expenditures for property and equipment	(3,081)		(2,343)		Expenditures for property and equipment	(5,062)		(4,461)
Net cash (used in) provided by investing activities		(10,669)		12,186
Net cash used in investing activities						Net cash used in investing activities	(13,666)		(2,757)
Financing activities:	Financing activities:					Financing activities:
Net proceeds from common stock issuance	Net proceeds from common stock issuance	1,465		3,781		Net proceeds from common stock issuance	2,211		7,621
Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards	Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards	(943)		(1,501)		Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards	(1,441)		(1,562)
Other	Other	(19)		(18)		Other	(18)		(16)
Net cash provided by financing activities	Net cash provided by financing activities	503		2,262		Net cash provided by financing activities	752		6,043
Net (decrease) increase in cash, cash equivalents, and restricted cash	Net (decrease) increase in cash, cash equivalents, and restricted cash	(6,698)		24,534		Net (decrease) increase in cash, cash equivalents, and restricted cash	(6,303)		18,141
Cash, cash equivalents, and restricted cash at beginning of period	Cash, cash equivalents, and restricted cash at beginning of period	68,541		33,831		Cash, cash equivalents, and restricted cash at beginning of period	68,541		33,831
Cash, cash equivalents, and restricted cash at end of period	Cash, cash equivalents, and restricted cash at end of period	$	61,843	$	58,365	Cash, cash equivalents, and restricted cash at end of period	$	62,238	$	51,972

Table of Contents

VERICEL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(Unaudited, amounts in thousands)


		Three months ended March 31,			Six Months Ended June 30,
		2022	2021		2022	2021
Supplemental disclosure of cash flow information:	Supplemental disclosure of cash flow information:			Supplemental disclosure of cash flow information:
Non-cash information:	Non-cash information:			Non-cash information:

Additions to property and equipment included in accounts payable	Additions to property and equipment included in accounts payable	317	530	Additions to property and equipment included in accounts payable	869	630
Restricted stock held for employee tax remittance included in accounts payable	Restricted stock held for employee tax remittance included in accounts payable	480	65	Restricted stock held for employee tax remittance included in accounts payable	—	61


		Three months ended March 31,					Six Months Ended June 30,
		2022		2021			2022		2021
Reconciliation of amounts within the condensed consolidated balance sheets:	Reconciliation of amounts within the condensed consolidated balance sheets:					Reconciliation of amounts within the condensed consolidated balance sheets:
Cash and cash equivalents	Cash and cash equivalents	$	55,659	$	58,154	Cash and cash equivalents	$	56,054	$	51,761
Restricted cash	Restricted cash	6,184		211		Restricted cash	6,184		211
Total cash, cash equivalents, and restricted cash at end of period	Total cash, cash equivalents, and restricted cash at end of period	$	61,843	$	58,365	Total cash, cash equivalents, and restricted cash at end of period	$	62,238	$	51,972

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

Table of Contents

VERICEL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization

Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets 2 cell therapy products in the U.S., MACI® (autologous cultured chondrocytes on porcine collagen membrane) and Epicel® (cultured epidermal autografts).

MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid®, a registration-stage biological orphan product designed for the debridement of severe thermal burns. The Company operates its business primarily in the U.S. in 1 reportable segment — the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.

COVID-19

The ongoing pandemic caused by the spread of a novel strain of coronavirus (“COVID-19”) has created significant disruptions to the U.S. and global economy and has contributed to significant volatility in financial markets. The global impact of the outbreak has fluctuated since early 2020. At times, many state, local and national governments – including those in Massachusetts and Michigan, where the Company’s operations are located – have responded by issuing, extending and supplementing orders requiring quarantines, restrictions on travel, and the mandatory closure of certain non-essential businesses, among other actions. In the U.S., the status and application of these orders have varied on a state-by-state basis since the early days of the pandemic. Many of the restrictions have been periodically updated as infection rates in the U.S. have risen and fallen, as new virus variants have emerged, as vaccines have been distributed and administered, and as world health leaders learn more about the virus, its transmission pathway and who is most at risk. Because Vericel is deemed an essential business, the Company has been exempted from government orders requiring the closure of workplaces and the cessation of business operations. The vast majority of these restrictions have since been rescinded throughout most of the U.S.

Notwithstanding being an essential business, the Company’s business and operations at times have been adversely impacted by the ongoing effects of the COVID-19 pandemic. For example, as a result of periodic restrictions placed on the performance of elective surgical procedures, Vericel experienced a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders during March and April of 2020. The widespread suspension of surgical procedures impacted the Company’s business and operations during the first and second quarters of 2020. The level and degree of restriction on elective surgeries, on the ability of patients to seek treatment and on U.S. business operations generally fluctuated throughout 2020 as COVID-19 infection rates rose and fell during the summer months and into the autumn. By the first quarter of 2021, the pandemic’s effects on the Company’s MACI business had largely dissipated. During the summer of 2021, however, the pandemic’s direct and ancillary effects again began to cause some disruption to the Company’s MACI business. Following the cessation of COVID-19-related travel restrictions in many parts of the U.S. and the availability of vaccinations in May and June 2021, some MACI patients postponed or delayed treatment. Further, surges of new COVID-19 cases during the second half of 2021 caused by the spread of the “Delta” and “Omicron” variants again caused disruptions to health care networks including restrictions on the performance of elective procedures, the availability of physicians and/or their treatment prioritizations, the level of healthcare facility staffing and, in some instances, the willingness or ability of patients to seek treatment. Consequently, and notwithstanding the widespread distribution of vaccines, these factors contributed to a slowdown of MACI procedures during the third and fourth quarters of 2021 and during the first ~~months~~and second quarters of 2022. Although hospitals are now better prepared for subsequent surges in COVID-19 patients, the risk remains that regional or local restrictions could again be placed on the performance of elective surgical procedures if the number of COVID-19 infections in the U.S. were to rise, or if new or existing COVID-19 variants render current vaccine treatments ineffective.

Because Epicel is used almost exclusively in an emergent setting by burn centers and surgeons throughout the country, Epicel revenue and procedure volumes have been less affected by the pandemic. Nevertheless, the number of large burns and burn admissions can be affected by restrictions on human activity resulting from more severe government lockdown orders.

At the outset of the pandemic, the Company put in place a comprehensive workplace protection plan, which instituted protective measures in response to COVID-19. Vericel’s workplace protection plan has closely followed guidance issued by the Centers for Disease Control and Prevention (“CDC”) and has complied with applicable federal and state law. To date, Vericel

~~Table of Contents~~

has been successful in sustaining its operations and providing MACI and Epicel to patients in need. The Company continues to

Table of Contents

review its policies and procedures regularly, including its workplace protection plan, as the pandemic evolves and the Company may take additional actions to the extent required.

The Company continues to manufacture MACI and Epicel and is maintaining a significant safety stock of all key raw materials. Vericel does not expect that current supply chain interruptions will impact its ongoing manufacturing operations. With respect to customer delivery, MACI final product has an established shelf life of six (6) days and an established shipping shelf life of three (3) days. Currently, MACI is picked up by courier and shipped by commercial air or ground transportation to customer surgical sites. Epicel final product has an established shelf life of 48 hours and is hand carried to customer hospitals by courier. Transportation is primarily by commercial or charter airline. Although the Company has not experienced material shipping delays, ~~or materially increased costs to date,~~ significant disruption of air travel could result in the inability to deliver MACI or Epicel final products to customer sites within appropriate timeframes, which could further adversely impact the Company’s business. At this time, the Company is not aware of COVID-19 related impacts on its distributors, operations or third-party service providers’ ability to manage patient cases. The Company believes it is possible that it could experience variable business impacts, ~~on our business,~~ should a new resurgence of COVID-19 infections occur in the future.

The Conflict in Ukraine

The current conflict between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are creating substantial uncertainty in the global economy and resulting in heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these unaudited condensed consolidated financial statements.

Liquidity

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of ~~March 31,~~June 30, 2022, the Company had an accumulated deficit of $~~390.4~~399.3 million and had a net loss of ~~$7.1~~$16.1 million during the ~~three~~six months ended ~~March 31,~~June 30, 2022. The Company had cash and cash equivalents of ~~$55.7~~$56.1 million and investments of ~~$67.7~~$68.4 million as of ~~March 31,~~June 30, 2022. The Company expects that cash from the sales of its products and existing cash, cash equivalents and investments will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. The effects of the COVID-19 pandemic continue to evolve, however. To the extent the U.S. experiences a worsening in COVID-19 infections or the emergence of additional virus variants that result in more serious disease or limit the effectiveness of existing vaccines, subsequent healthcare measures – to include the postponement or cessation of elective and other surgical procedures – may cause the Company to experience a reduction in business and resulting revenue. This, consequently, may result in irrecoverable losses of customers and significantly impact the Company’s long-term liquidity, potentially requiring the Company to engage in layoffs, furloughs and/or reductions in salaries. The Company also may need to access additional capital; however, the Company may not be able to obtain financing on acceptable terms or at all, particularly in light of the impact of COVID-19 on the global economy and financial markets. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders.

2. Basis of Presentation

The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.

The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact ~~its~~the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future

Table of Contents

developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to continue to contain or treat COVID-19, as well as the economic impact on its customers. The Company has made estimates of the impact of the COVID-19 pandemic within these financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates. As of ~~March 31,~~June 30, 2022, the Company has not recorded impairments to investments, inventory, other current assets or long-lived assets as a result of the COVID-19 pandemic.

The condensed consolidated balance sheet atas of December 31, 2021 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial

~~Table of Contents~~

statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on February 24, 2022 (“Annual Report”).

Recent Accounting Pronouncements

No new ~~Accounting Standards~~accounting standards were adopted during the quarter ended ~~March 31,~~June 30, 2022.

3. Revenue

Revenue Recognition and Net Product Sales

The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and other sources following the five-step model in Accounting Standards Codification 606, Revenue Recognition.

MACI Biopsy Kits

MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.

MACI Implants

The Company contracts with 2 specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc.(“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration which the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration.

When the Company sells MACI, the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments -

Table of Contents

Credit Losses. The Company assesses risk and determines a loss percentage by pooling account receivables based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of ~~March 31,~~June 30, 2022. The total allowance for uncollectible consideration as of ~~March 31,~~June 30, 2022 and December 31, 2021 was $6.7 million and $7.0 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the ~~three~~six months ended ~~March 31,~~June 30, 2022.

~~Table of Contents~~

Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year. During the three months ended June 30, 2022, the Company recorded changes in estimates for MACI implants that occurred in a prior year of approximately $1.4 million, related to claims billed through a third-party insurer as a result of finalization of the billing claims processes.

Epicel

The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital.

NexoBrid

The Company entered into exclusive license and supply agreements with MediWound in May 2019, under which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. The U.S. Biomedical Advanced Research and Development Authority (“BARDA”) has committed to procure NexoBrid from MediWound and, as of ~~March 31,~~June 30, 2022, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product. The Company recognizes revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA is in control of the product.

Revenue by Product and Customer

The following table and descriptions below show the products from which the Company generated its revenue:

Three Months Ended March 31,
Revenue by product (in thousands) 2022 2021
MACI implants and kits
Implants based on contracted rates sold through a specialty pharmacy (a)
$ 15,190 $ 13,206
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
3,369 4,280
Implants sold direct based on contracted rates (c)
5,634 4,466
Implants sold direct subject to third-party reimbursement (d)
861 849
Biopsy kits - direct bill 522 519
Change in estimates related to prior periods (e)
419 477
Total MACI implants and kits 25,995 23,797
Epicel
Direct bill (hospital) 9,857 9,830
NexoBrid revenue (f)
222 941
Total revenue $ 36,074 $ 34,568
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini or AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound.

Table of Contents


	Three Months Ended June 30,				Six Months Ended June 30,
Revenue by product (in thousands)	2022		2021		2022		2021
MACI implants and kits
Implants based on contracted rates sold through a specialty pharmacy (a)	$	15,714	$	17,972	$	31,009	$	31,200
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	4,295		3,502		7,803		7,917
Implants sold direct based on contracted rates (c)	5,756		4,487		11,390		8,954
Implants sold direct subject to third-party reimbursement (d)	570		405		1,441		1,255
Biopsy kits - direct bill	545		551		1,066		1,070
Change in estimates related to prior periods (e)	1,733		(392)		1,898		(74)
Total MACI implants and kits	28,613		26,525		54,607		50,322
Epicel
Direct bill (hospital)	8,213		12,155		18,071		21,985

NexoBrid revenue (f)	220		839		442		1,780
Total revenue	$	37,046	$	39,519	$	73,120	$	74,087

(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.

(b) Represents implants sold through Orsini or AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.

(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.

(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.

(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare, and relate primarily to changes to the initial expected reimbursement or collection expectation upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.

(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see note 10).

Concentration of Credit Risk

The Company’s total revenue concentration from an Epicel customer for the three and six months ended ~~March 31,~~June 30, 2022 was 6% and ~~2021 was 8%~~7%, respectively, and ~~14%~~11% and 12%, ~~respectively.~~respectively, for the same periods in 2021. For the Company’s total accounts receivable balances, there were no customers as of ~~March 31,~~June 30, 2022 or December 31, 2021, with a concentration greater than 10%.

Table of Contents

4. Selected Balance Sheet Components

Inventory

Inventory as of ~~March 31,~~June 30, 2022 and December 31, 2021:


(In thousands)	(In thousands)	March 31, 2022		December 31, 2021		(In thousands)	June 30, 2022		December 31, 2021
Raw materials	Raw materials	$	13,264	$	12,676	Raw materials	$	15,175	$	12,676
Work-in-process	Work-in-process	1,057		644		Work-in-process	683		644
Finished goods	Finished goods	64		61		Finished goods	71		61
Total inventory	Total inventory	$	14,385	$	13,381	Total inventory	$	15,929	$	13,381

Property and Equipment

Property and Equipment, net as of ~~March 31,~~June 30, 2022 and December 31, 2021:


(In thousands)	(In thousands)	March 31, 2022		December 31, 2021		(In thousands)	June 30, 2022		December 31, 2021
Machinery and equipment	Machinery and equipment	$	4,514	$	4,522	Machinery and equipment	$	4,615	$	4,522
Furniture, fixtures and office equipment	Furniture, fixtures and office equipment	1,551		1,551		Furniture, fixtures and office equipment	1,710		1,551
Computer equipment and software	Computer equipment and software	7,934		7,769		Computer equipment and software	8,112		7,769
Leasehold improvements	Leasehold improvements	10,616		10,617		Leasehold improvements	13,134		10,617
Construction in process	Construction in process	4,966		3,097		Construction in process	4,543		3,097
Financing right-of-use lease	Financing right-of-use lease	65		74		Financing right-of-use lease	55		74
Total property and equipment, gross	Total property and equipment, gross	29,646		27,630		Total property and equipment, gross	32,169		27,630
Less accumulated depreciation	Less accumulated depreciation	(15,195)		(14,322)		Less accumulated depreciation	(16,250)		(14,322)
Total property and equipment, net	Total property and equipment, net	$	14,451	$	13,308	Total property and equipment, net	$	15,919	$	13,308

Depreciation expense for the three and six months ended ~~March 31,~~June 30, 2022 ~~and 2021~~ was ~~$0.9~~$1.1 million and ~~$0.8~~$1.9 million, ~~respectively.~~respectively, and $0.7 million and $1.5 million, respectively, for the same periods in 2021.

Accrued Expenses

Accrued Expenses as of ~~March 31,~~June 30, 2022 and December 31, 2021 are as follows:


(In thousands)	(In thousands)	March 31, 2022		December 31, 2021		(In thousands)	June 30, 2022		December 31, 2021
Bonus related compensation	Bonus related compensation	$	2,483	$	6,305	Bonus related compensation	$	3,942	$	6,305
Employee related accruals	Employee related accruals	3,112		3,616		Employee related accruals	3,555		3,616
Insurance reimbursement-related liabilities	Insurance reimbursement-related liabilities	5,111		3,973		Insurance reimbursement-related liabilities	4,585		3,973
Other accrued expenses	Other accrued expenses	87		151		Other accrued expenses	51		151
Total accrued expenses	Total accrued expenses	$	10,793	$	14,045	Total accrued expenses	$	12,133	$	14,045

5. Leases

The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, vehicles and computer equipment.

~~Table of Contents~~

On January 28, 2022, the Company entered into a ~~Lease Agreement~~lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

The term of the Burlington Lease is ~~scheduled~~currently expected to begin in 2023, 12 months following the landlord’s commencement of construction of the core and shell of the building in which the Premises are located ~~which is currently expected to be February 28, 2023~~ (the “Commencement Date”).

Table of Contents

The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a ~~one-time~~1-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $25.1 million in total, towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet, when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date.

In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three and six months ended ~~March 31,~~June 30, 2022 and 2021, lease expense of less than $0.1 million was recorded related to short-term leases. For the three and six months endedJune 30, 2022~~March 31, 2022 and~~ ~~2021,~~, the Company recognized $1.7 million and ~~$1.9~~$3.5 million, respectively, of operating lease ~~expense.~~expense and $1.8 million and $3.7 million, respectively, for the same periods in 2021. For the three and six months ended~~March 31,~~June 30, 2022 and 2021, the Company recognized less than $0.1 million of financing lease expense.

Operating and finance lease assets and liabilities are as follows:


(In thousands)	(In thousands)	Classification	March 31, 2022		December 31, 2021		(In thousands)	Classification	June 30, 2022		December 31, 2021
Assets	Assets						Assets
Operating	Operating	Right-of-use assets	$	44,653	$	45,720	Operating	Right-of-use assets	$	43,583	$	45,720
Finance	Finance	Property and equipment, net	65		73		Finance	Property and equipment, net	55		73
Total leased assets	Total leased assets		$	44,718	$	45,793	Total leased assets		$	43,638	$	45,793
Liabilities	Liabilities						Liabilities
Current	Current						Current
Operating	Operating	Current portion of operating lease liabilities	$	3,147	$	2,950	Operating	Current portion of operating lease liabilities	$	3,156	$	2,950
Finance	Finance	Other current liabilities	41		41		Finance	Other current liabilities	41		41
			$	3,188	$	2,991
Non-current	Non-current						Non-current
Operating	Operating	Operating lease liabilities	$	46,053	$	47,147	Operating	Operating lease liabilities	44,964		47,147
Finance	Finance	Other long-term liabilities	19		44		Finance	Other long-term liabilities	21		44
Total leased liabilities	Total leased liabilities		$	46,072	$	47,191	Total leased liabilities		$	48,182	$	50,182

6. Stock-Based Compensation

The 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity

~~Table of Contents~~

Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (“Prior Plans”), and no new grants have been granted under the Prior Plans after ~~approval.~~approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.

Table of Contents

Stock Compensation Expense

Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	(in thousands)	2022		2021			(in thousands)	2022		2021		2022		2021
Cost of product sales	Cost of product sales	$	1,118	$	911		Cost of product sales	$	1,035	$	1,287	$	2,153	$	2,199
Research and development	Research and development	1,350		863			Research and development	1,520		1,234		2,870		2,096
Selling, general and administrative	Selling, general and administrative	7,063		5,245			Selling, general and administrative	8,253		8,345		15,316		13,590
Total non-cash stock-based compensation expense	Total non-cash stock-based compensation expense	$	9,531	$	7,019		Total non-cash stock-based compensation expense	$	10,808	$	10,866	$	20,339	$	17,885

Service-Based Stock Options

During the three and six months ended ~~March 31,~~June 30, 2022, ~~and 2021,~~ the Company granted service-based options to purchase common stock of ~~993,589~~170,060 and ~~1,337,955, respectively.~~1,163,649, respectively, and 136,117 and 1,474,072, respectively, for the same periods in 2021. The weighted-average grant-date fair value of service-based options granted during the three and six months ended ~~March 31,~~June 30, 2022 was $19.25 and ~~2021 was $20.99 and $32.02~~$20.74 per option, ~~respectively.~~respectively, and $39.31 and $32.69, respectively, for the same periods in 2021.

Restricted Stock Units

During the three and six months ended ~~March 31,~~June 30, 2022, ~~and 2021,~~ the Company granted ~~343,022~~39,746 and ~~214,113~~382,768 restricted stock units, ~~respectively.~~respectively, and 26,941 and 241,054, respectively, for the same periods in 2021. The weighted-average grant-date fair value of restricted stock units granted during the three and six months ended ~~March 31,~~June 30, 2022 was $31.94 and ~~2021 was $34.97 and $50.81~~$34.65 per unit, ~~respectively.~~respectively, and $61.37 and $51.99, respectively, for the same periods in 2021.

7. Investments

Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities as of ~~March 31,~~June 30, 2022 and December 31, 2021:


		March 31, 2022											June 30, 2022
				Gross Unrealized						Estimated Fair Value					Gross Unrealized						Estimated Fair Value
(In thousands)	(In thousands)	Amortized Cost		Gains		Losses		Credit Losses				(In thousands)	Amortized Cost		Gains		Losses		Credit Losses
Commercial paper	Commercial paper	$	15,241	$	—	$	(38)	$	—	$	15,203	Commercial paper	$	15,784	$	—	$	(76)	$	—	$	15,708
Corporate notes	Corporate notes	53,063		—		(575)		—		52,488		Corporate notes	53,428		—		(780)		—		52,648
		$	68,304	$	—	$	(613)	$	—	$	67,691		$	69,212	$	—	$	(856)	$	—	$	68,356
Classified as:	Classified as:											Classified as:
Short-term investments	Short-term investments									$	44,888	Short-term investments									$	44,638
Long-term investments	Long-term investments									22,803		Long-term investments									23,718
										$	67,691										$	68,356


	December 31, 2021
			Gross Unrealized						Estimated Fair Value
(In thousands)	Amortized Cost		Gains		Losses		Credit Losses
Commercial paper	$	10,243	$	—	$	(12)	$	—	$	10,231
Corporate notes	50,666		—		(142)		—		50,524
	$	60,909	$	—	$	(154)	$	—	$	60,755
Classified as:
Short-term investments									$	35,068
Long-term investments									25,687
									$	60,755

1516

Table of Contents

December 31, 2021
Gross Unrealized Estimated Fair Value
(In thousands) Amortized Cost Gains Losses Credit Losses
Commercial paper $ 10,243 $ — $ (12) $ — $ 10,231
Corporate notes 50,666 — (142) — 50,524
$ 60,909 $ — $ (154) $ — $ 60,755
Classified as:
Short-term investments $ 35,068
Long-term investments 25,687
$ 60,755

As of ~~March 31,~~June 30, 2022 and December 31, 2021, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three and six months ended ~~March 31,~~June 30, 2022 and 2021.

8. Fair Value Measurements

The Company’s fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper and corporate notes are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2021 to ~~March 31,~~June 30, 2022.

The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:


		March 31, 2022								December 31, 2021									June 30, 2022								December 31, 2021
				Fair value measurement category								Fair value measurement category									Fair Value Measurement Category								Fair Value Measurement Category
(In thousands)	(In thousands)	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		(In thousands)	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Assets:	Assets:																	Assets:
Money market funds	Money market funds	$	1,884	$	1,884	$	—	$	—	$	1,258	$	1,258	$	—	$	—	Money market funds	$	1,135	$	1,135	$	—	$	—	$	1,258	$	1,258	$	—	$	—
Commercial paper (a)	Commercial paper (a)	15,203		—		15,203		—		18,229		—		18,229		—		Commercial paper (a)	15,708		—		15,708		—		18,229		—		18,229		—
Corporate notes	Corporate notes	52,488		—		52,488		—		50,524		—		50,524		—		Corporate notes	52,648		—		52,648		—		50,524		—		50,524		—
		$	69,575	$	1,884	$	67,691	$	—	$	70,011	$	1,258	$	68,753	$	—		$	69,491	$	1,135	$	68,356	$	—	$	70,011	$	1,258	$	68,753	$	—

(a) Approximately $8.0 million of commercial paper had an original maturity of 90 days or less and was recorded as a cash equivalent as of December 31, 2021.

The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost which approximates fair value.

Table of Contents

9. Net Loss Per Common Share

A summary of net loss per common share is presented below:

~~Table of Contents~~


		Three Months Ended March 31,					Three Months Ended June 30,				Six months ended June 30,
(Amounts in thousands, except per share amounts)	(Amounts in thousands, except per share amounts)	2022		2021				(Amounts in thousands, except per share amounts)	2022		2021		2022		2021
Net loss	Net loss	$	(7,091)	$	(3,289)			Net loss	$	(8,963)	$	(3,786)	$	(16,054)	$	(7,075)

Basic weighted-average common shares outstanding	Basic weighted-average common shares outstanding	46,985		45,984				Basic weighted-average common shares outstanding	47,117		46,403		47,052		46,195
Effect of dilutive stock options and restricted stock units	Effect of dilutive stock options and restricted stock units	—		—				Effect of dilutive stock options and restricted stock units	—		—		—		—
Diluted weighted-average common shares outstanding	Diluted weighted-average common shares outstanding	46,985		45,984				Diluted weighted-average common shares outstanding	47,117		46,403		47,052		46,195

Basic loss per common share	Basic loss per common share	$	(0.15)	$	(0.07)			Basic loss per common share	$	(0.19)	$	(0.08)	$	(0.34)	$	(0.15)
Diluted loss per common share	Diluted loss per common share	$	(0.15)	$	(0.07)			Diluted loss per common share	$	(0.19)	$	(0.08)	$	(0.34)	$	(0.15)

Anti-dilutive shares excluded from diluted net loss per common share:	Anti-dilutive shares excluded from diluted net loss per common share:					Anti-dilutive shares excluded from diluted net loss per common share:
Stock options	Stock options	6,479		6,183				Stock options	6,586		5,960		6,586		5,960
Restricted stock units	Restricted stock units	625		406				Restricted stock units	636		413		636		413

10. NexoBrid License and Supply Agreements

On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid and any improvements to NexoBrid in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns. On June 29, 2021, the Company announced that MediWound had received a complete response letter (“CRL”) from the U.S. Food & Drug Administration (“FDA”) with respect to a biologics license application (“BLA”), which MediWound had previously submitted to the FDA seeking marketing approval for the product in the U.S. As part of the ~~complete response letter,~~CRL, the FDA communicated to MediWound that it had completed its review of the BLA, as amended, and had determined that it ~~cannot~~could not approve the BLA in its ~~present~~then form. The Company ~~continues~~has continued to work with MediWound, BARDA and the FDA to address the issues identified in the ~~agency’s complete response letter, to prepare~~CRL. On July 1, 2022, the Company and ~~submit~~MediWound submitted a BLA resubmission to the FDA to address the issues identified by the FDA in the CRL. Subsequently, the FDA informed the Company that it has accepted the resubmission for review and ~~to seek the potential approval~~has established a Prescription Drug User Fee Act (“PDUFA”) date for completing that review of ~~NexoBrid.~~January 1, 2023.

Pursuant to the terms of the license agreement, if the BLA is approved, MediWound will transfer the BLA to Vericel and Vericel will market NexoBrid in the U.S. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.

In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. The Company is also obligated to pay MediWound $7.5 million, which is contingent upon U.S. regulatory approval of the BLA for NexoBrid and up to $125.0 million contingent upon meeting certain sales milestones. The first sales milestone of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of ~~March 31,~~June 30, 2022, the milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. The Company also entered into a supply agreement with MediWound under which MediWound will manufacture NexoBrid for the Company on a unit price basis which may be increased based on a published index. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply.

BARDA has committed to procure NexoBrid directly from MediWound under an emergency use authorization, and under such commitment the Company will receive a percentage of gross profit for sales directly to BARDA. If BARDA procures NexoBrid directly from Vericel, the Company will pay a percentage of gross profits to MediWound on initial committed amounts and a royalty on any additional BARDA purchases of NexoBrid beyond the initial committed amount. As of ~~March 31,~~June 30, 2022, the Company does not hold a direct contract or distribution agreement with BARDA.

1718

Table of Contents

11. Commitments and Contingencies

From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of ~~March 31,~~June 30, 2022, the Company ~~has~~had no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

12. Subsequent Events

On July 29, 2022, the Company, as borrower, entered into a $150 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15 million sub-facility for the issuance of letters of credit. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company.

Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) SOFR plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s total net leverage ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s total net leverage ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s total net leverage ratio.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company and a leader in advanced therapies and for sports medicine and severe burn care markets. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products in the U.S. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® is a permanent skin replacement Humanitarian Use Device (“HUD”) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). We also hold an exclusive license from MediWound for North American rights to NexoBrid®, a registration-stage biological orphan product designed for the debridement of severe thermal burns. In 2020, MediWound submitted to the FDA a biologics license application (“BLA”) seeking the approval of NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. The FDA accepted the BLA for filing and assigned a Prescription Drug User Fee Act (“PDUFA”) target date of June 29, 2021. Thereafter, on June 29, 2021, MediWound received a complete response letter (“CRL”) from the FDA regarding the BLA through which the FDA communicated to MediWound that it had completed its review of the BLA, as amended, and had determined that it could not approve the BLA in its ~~present~~then form. We ~~continue~~have continued to work with MediWound, BARDA and the FDA to address the issues identified byin the ~~FDA, to prepare~~CRL. On July 1, 2022, Vericel and ~~submit a~~MediWound submitted the BLA resubmission to the FDA ~~and to seek~~seeking the potential approval of NexoBrid. Subsequently, the FDA informed us that it has accepted the resubmission for review and has established a PDUFA date for completing that review of January 1, 2023.

COVID-19

The ongoing pandemic caused by the spread of a novel strain of coronavirus (“COVID-19”) has created significant disruptions to the U.S. and global economy and has contributed to significant volatility in financial markets. The global impact of the ~~pandemic~~outbreak has fluctuated since early 2020. At times, many state, local and national governments – including those in Massachusetts and Michigan, where ~~our~~the Company’s operations are located – have responded by issuing, extending and supplementing orders requiring quarantines, restrictions on travel, and the mandatory closure of certain non-essential businesses, among other actions. In the U.S., the status and application of these orders have varied on a state-by-state basis since the early days of the pandemic. Many of the restrictions have been periodically updated as infection rates in the U.S. have risen and fallen, as new virus variants have emerged, as vaccines have been distributed and administered, and as world health leaders learn more about the virus, its transmission pathway and who is most at risk. Because Vericel is deemed an essential business, ~~we were~~it has been exempted from government orders requiring the closure of workplaces and the cessation of business operations. The vast majority of these restrictions have since been rescinded throughout most of the U.S.

Notwithstanding being an essential business, our business and operations at times have been adversely impacted by the ongoing effects of the COVID-19 pandemic. For example, as a result of periodic restrictions placed on the performance of elective surgical procedures, Vericel experienced a significant increase in cancellations of scheduled MACI procedures as well as a slowdown in new MACI orders during March and April of 2020. The widespread suspension of surgical procedures impacted our business and operations during the first and second quarters of 2020. The level and degree of restriction on elective surgeries, on the ability of patients to seek treatment and on U.S. business operations generally fluctuated throughout 2020 as COVID-19 infection rates rose and fell during the summer months and into the autumn. By the first quarter of 2021, the pandemic’s effects on our MACI business had largely dissipated. During the summer of 2021, however, the pandemic’s direct and ancillary effects again began to cause some disruption to our MACI business. Following the cessation of COVID-19-related travel restrictions in many parts of the U.S. and the availability of vaccinations in May and June 2021, some MACI patients postponed or delayed treatment. Further, surges of new COVID-19 cases during the second half of 2021 caused by the spread of the “Delta” and “Omicron” variants again caused disruptions to health care networks including restrictions on the performance of elective surgical procedures, the availability of physicians and/or their treatment prioritizations, the level of healthcare facility staffing and, in some instances, the willingness or ability of patients to seek treatment. Consequently, and notwithstanding the widespread distribution of vaccines, these factors contributed to a slowdown of MACI procedures during the third and fourth quarters of 2021 and during the first ~~months~~and second quarters of 2022. Although hospitals are now better prepared for subsequent surges in COVID-19 patients, the risk remains that regional or local restrictions could again be placed on the performance of elective surgical procedures if the number of COVID-19 infections in the U.S. were to continue to rise, or if new or existing COVID-19 variants render current vaccine treatments ineffective.

At the outset of the pandemic, we put in place a comprehensive workplace protection plan, which instituted protective measures in response to COVID-19. Our workplace protection plan has closely followed guidance issued by the Centers for

1920

Table of Contents

Disease Control and Prevention (“CDC”) and has complied with applicable federal and state law. To date, Vericel has been successful in sustaining its operations and providing MACI and Epicel to patients in need. We continue to review our policies and procedures regularly, including our workplace protection plan, as the pandemic evolves and we may take additional actions to the extent required.

We continue to manufacture MACI and Epicel and are maintaining a significant safety stock of all key raw materials. We do not expect current supply chain interruptions will impact our ongoing manufacturing operations. With respect to customer delivery, MACI final product has an established shelf life of six (6) days and an established shipping shelf life of three (3) days. Currently, MACI is picked up by courier and shipped by commercial air or ground transportation to customer surgical sites. Epicel final product has an established shelf life of 48 hours and is hand-carried to customer hospitals by courier. Transportation is primarily by commercial or charter airline. Although we have not experienced material shipping delays, ~~or materially-increased costs to date,~~ significant disruption of air travel could result in the inability to deliver MACI or Epicel final products to customer sites within appropriate timeframes, which could further adversely impact our business. At this time, we are not aware of COVID-19-related impacts on our distributors, operations or third-party service providers’ ability to manage patient cases.

We believe it is possible that we could continue to experience variable impacts on our business, should a new resurgence of COVID-19 infections occur in the future. Measures taken to limit the impact of COVID-19 at the international, national and local levels, including the availability and effectiveness of COVID-19 vaccines, shelter-in-place orders, social distancing measures, travel bans and restrictions, and business and government shutdowns, may again create significant negative economic impacts on a global basis. Given that uncertainty, we cannot accurately estimate the extent to which the ongoing COVID-19 pandemic may continue to impact utilization and revenue of our products in 2022 and beyond.

The Conflict in Ukraine

The current conflict between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are creating substantial uncertainty in the global economy and resulting in heightened inflation and supply chain disruptions. While we do not have operations in Russia or Ukraine and do not have exposure to distributors, or third-party service providers in Russia or Ukraine, we are unable to predict the impact that these actions will have on the global economy or on our financial condition, results of operations, and cash flows as of the date of these unaudited condensed consolidated financial statements.

Manufacturing

We have a cell manufacturing facility in Cambridge, Massachusetts which is used for U.S. manufacturing and distribution of MACI and Epicel.

Product Portfolio

Our marketed products include two FDA-approved autologous cell therapies: MACI, a third-generation autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults, and Epicel, a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of TBSA. Both products are currently marketed in the U.S. In addition, we have entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America, if approved by the FDA.

MACI

MACI is a third-generation autologous chondrocyte implantation (“ACI”) product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Our target audience of U.S. physicians is approximately 5,000 orthopedic surgeons and is divided into two segments: a group of orthopedic surgeons who self-identify and/or have a formal specialty as sports medicine physicians, and a subpopulation of general orthopedic surgeons who perform a high volume of cartilage repair procedures. As of the date of this report, we have 76 MACI sales representatives to enable the sales force to reach our target audience. Most private payers have a medical policy that covers treatment with MACI with the top 30 largest commercial payers having a formal medical policy for MACI or ACI in general. With respect to private commercial payers that have not yet approved a medical policy for MACI, we often obtain approval on a case-by-case basis.

Table of Contents

Epicel

Epicel is a permanent skin replacement for deep-dermal or full-thickness burns greater than or equal to 30 percent of TBSA. Epicel is regulated by the Center for Biologics Evaluation and Research (“CBER”) of the FDA under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns. Epicel was designated as a HUD in 1998 and an HDE application for the product was submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S. Under an HDE approval, a HUD cannot be sold for an amount that exceeds the cost of research and development, fabrication and distribution unless certain conditions are met. A HUD is eligible to be sold for profit after receiving HDE approval if the device meets certain

~~Table of Contents~~

eligibility criteria, including where the device is intended for the treatment of a disease or condition that occurs in pediatric patients and such device is labeled for use in pediatric patients. If the FDA determines that a HUD meets the eligibility criteria, the HUD is permitted to be sold for profit so long as the number of devices distributed in any calendar year does not exceed the Annual Distribution Number (“ADN”). The ADN is defined as the number of devices reasonably needed to treat a population of 8,000 individuals per year in the U.S.

On February 18, 2016, the FDA approved our HDE supplement to revise the labeled indications of use for Epicel to specifically include pediatric patients. The revised product label also now specifies that the probable benefit of Epicel, mainly related to survival, was demonstrated in two Epicel clinical experience databases and a physician-sponsored study comparing outcomes in patients with massive burns treated with Epicel relative to standard care. Because of the change in the label to specifically include use in pediatric patients, Epicel is no longer subject to the HDE profit restrictions. In conjunction with adding the pediatric labeling and meeting the pediatric eligibility criteria, the FDA has determined the ADN number for Epicel to be 360,400 which is approximately 30 times larger than the volume of grafts sold in 2021. We currently have a thirteen-person burn field force comprised of seven account managers and six burn clinical specialists, led by atwo regional directors and aone national sales director.

NexoBrid

Our development portfolio includes NexoBrid, a registration-stage, topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns. We have entered into exclusive license and supply agreement with MediWound to commercialize NexoBrid and any improvements to the product in North America, if approved. On June 29, 2021, the Company announced that MediWound had received a ~~complete response letter~~CRL from the FDA with respect to the BLA, which MediWound had previously submitted to the FDA seeking marketing approval for the product in the U.S. As part of the ~~complete response letter,~~CRL, the FDA communicated to MediWound that it had completed its review of the BLA, as amended, and had determined that it ~~cannot~~could not approve the BLA in its ~~present~~then form. We ~~continue~~have continued to work with MediWound, BARDA and the FDA to address the issues identified in the ~~agency’s complete response letter, to prepare~~CRL. On July 1, 2022, Vericel and ~~submit~~MediWound submitted a BLA resubmission to the FDA to address the issues identified by the FDA in the CRL. Subsequently, the FDA informed us that is has accepted the resubmission for review and ~~to seek the potential approval~~has established a Prescription Drug User Fee Act (“PDUFA”) date for completing that review of ~~NexoBrid.~~January 1, 2023.

NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets. Pursuant to the terms of our existing license agreement, if the BLA is approved, MediWound will transfer the BLA to us and we will market NexoBrid in the U.S. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide development of NexoBrid in North America. Under our license agreement with MediWound, NexoBrid is being manufactured for BARDA prior to approval by the FDA under an emergency use authorization.

Table of Contents

Results of Operations

The following is a summary of our condensed consolidated results of operations:


		Three Months Ended March 31,								Three Months Ended June 30,								Six Months Ended June 30,
(In thousands)	(In thousands)	2022		2021		Change $		Change %			(In thousands)	2022		2021		Change $		Change %		2022		2021		Change $		Change %
Total revenue	Total revenue	$	36,074	$	34,568	$	1,506	4.4	%		Total revenue	$	37,046	$	39,519	$	(2,473)	(6.3)	%	$	73,120	$	74,087	$	(967)	(1.3)	%
Cost of product sales	Cost of product sales	12,622		11,583		1,039		9.0	%		Cost of product sales	14,192		12,609		1,583		12.6	%	26,814		24,192		2,622		10.8	%
Gross profit	Gross profit	23,452		22,985		467		2.0	%		Gross profit	22,854		26,910		(4,056)		(15.1)	%	46,306		49,895		(3,589)		(7.2)	%
Research and development	Research and development	4,860		3,630		1,230		33.9	%		Research and development	4,792		4,449		343		7.7	%	9,652		8,079		1,573		19.5	%
Selling, general and administrative	Selling, general and administrative	25,865		22,660		3,205		14.1	%		Selling, general and administrative	27,144		26,190		954		3.6	%	53,009		48,850		4,159		8.5	%
Total operating expenses	Total operating expenses	30,725		26,290		4,435		16.9	%		Total operating expenses	31,936		30,639		1,297		4.2	%	62,661		56,929		5,732		10.1	%
Loss from operations	Loss from operations	(7,273)		(3,305)		(3,968)		120.1	%		Loss from operations	(9,082)		(3,729)		(5,353)		143.6	%	(16,355)		(7,034)		(9,321)		132.5	%
Total other income	Total other income	182		159		23		14.5	%		Total other income	119		15		104		693.3	%	301		174		127		73.0	%
Income tax expense	Income tax expense	—		143		(143)		(100.0)	%		Income tax expense	—		72		(72)		(100.0)	%	—		215		(215)		(100.0)	%
Net loss	Net loss	$	(7,091)	$	(3,289)	$	(3,802)	115.6	%		Net loss	$	(8,963)	$	(3,786)	$	(5,177)	136.7	%	$	(16,054)	$	(7,075)	$	(8,979)	126.9	%

~~Table of Contents~~

Comparison of the Periods Ended ~~March 31,~~June 30, 2022 and 2021

Total Revenue

Revenue by product for the three and six months ended ~~March 31,~~June 30, 2022 and 2021 are as follows:


		Three Months Ended March 31,								Three Months Ended June 30,								Six Months Ended June 30,
Revenue by product (In thousands)	Revenue by product (In thousands)	2022		2021		Change $		Change %			Revenue by product (In thousands)	2022		2021		Change $		Change %		2022		2021		Change $		Change %
MACI	MACI	$	25,995	$	23,797	$	2,198	9.2	%		MACI	$	28,613	$	26,526	$	2,087	7.9	%	$	54,607	$	50,322	$	4,285	8.5	%
Epicel	Epicel	9,857		9,830		27		0.3	%		Epicel	8,213		12,154		(3,941)		(32.4)	%	18,071		21,985		(3,914)		(17.8)	%
NexoBrid	NexoBrid	222		941		(719)		(76.4)	%		NexoBrid	220		839		(619)		(73.8)	%	442		1,780		(1,338)		(75.2)	%
Total Revenue	Total Revenue	$	36,074	$	34,568	$	1,506	4.4	%		Total Revenue	$	37,046	$	39,519	$	(2,473)	(6.3)	%	$	73,120	$	74,087	$	(967)	(1.3)	%

Total revenue ~~increase~~decrease for the three and six months ended ~~March 31,~~June 30, 2022 compared to the same ~~period~~periods in 2021, was driven by ~~MACI volume~~a decrease in Epicel revenue and ~~price growth, partially offset by~~ lower revenues associated with the delivery of NexoBrid to BARDA for emergency response preparedness.

Seasonality. The effects of the ongoing COVID-19 pandemic have disrupted the normal seasonality of our MACI business at times over the past ~~twenty-five~~twenty-eight months. These effects have included, among others, periodic restrictions on the performance of elective surgical procedures throughout the country, the unavailability of physicians and/or changes to their treatment prioritizations, reductions in the levels of healthcare facility staffing and, in certain instances, the willingness or ability of patients to seek treatment and the inability of our clinical account specialists to call on surgeon customers. Over the last five years, ACI (MACI and Carticel prior to replacement) sales volumes from the first through the fourth quarter on average represented 19% (16%-21% range), 22% (16%-25% range), 23% (21%-26% range) and 36% (33%-38% range) respectively, of total annual volumes. MACI orders are normally stronger in the fourth quarter due to several factors including the satisfaction by patients of insurance deductible limits and the time of year patients prefer to start rehabilitation. Because of the effects of the COVID-19 pandemic, the MACI business seasonality in 2021 and 2020 did not follow our historical patterns, and seasonality in 2022 could continue to be impacted by COVID-19 related factors. Due to the low incidence and variable occurrence of severe burns, Epicel revenue has inherent variability from quarter-to-quarter and does not exhibit significant seasonality.

Gross Profit

Gross profit ~~increased~~decreased for the three and six months ended ~~March 31,~~June 30, 2022 compared to the same ~~period~~periods in 2021, asdriven by the reduction in revenue ~~growth more than offset increases~~over those periods in ~~stock compensation and offsite~~addition to higher external storage costs ~~as well as a reduction of NexoBrid revenue which has no associated cost of product sales~~.and manufacturing facility costs, lower Epicel labor utilization and raw material price increases.

Table of Contents

Research and Development Expenses

The following table summarizes research and development expenses, which include license fees, materials, professional fees and an allocation of employee-related salary and fringe benefit costs for our research and development projects:

Three Months Ended March 31,
(In thousands) 2022 2021 Change $ Change %
MACI $ 2,989 $ 1,888 $ 1,101 58.3 %
Epicel 1,220 934 286 30.6 %
NexoBrid 651 808 (157) (19.4) %
Total research and development expenses $ 4,860 $ 3,630 $ 1,230 33.9 %


	Three Months Ended June 30,								Six Months Ended June 30,
(In thousands)	2022		2021		Change $		Change %		2022		2021		Change $		Change %
MACI	$	2,972	$	2,533	$	439	17.3	%	$	5,961	$	4,421	$	1,540	34.8	%
Epicel	1,238		1,231		7		0.6	%	2,458		2,165		293		13.5	%
NexoBrid	582		685		(103)		(15.0)	%	1,233		1,493		(260)		(17.4)	%
Total research and development expenses	$	4,792	$	4,449	$	343	7.7	%	$	9,652	$	8,079	$	1,573	19.5	%

Research and development expenses for the three months ended ~~March 31,~~June 30, 2022 were ~~$4.9~~$4.8 million, compared to ~~$3.6~~$4.4 million for the same period in 2021. Research and development costs continue to be centered around process development, regulatory and medical affairs for MACI and Epicel. The increase is primarily due to additional spend on instrument design for Arthroscopic MACI delivery, offset by reimbursement of expenses related to the BLA resubmission.

Research and development expenses for the six months ended June 30, 2022 were $9.7 million, compared to $8.1 million for the same period in 2021. Research and development costs continue to be centered around process development, regulatory and medical affairs for MACI and Epicel. The increase is primarily due to an increase of ~~$0.5~~$0.8 million in stock-based compensation expense and additional spend on instrument design for Arthroscopic MACI ~~delivery.~~

~~Table~~delivery, offset by reimbursement of ~~Contents~~expenses related to the BLA resubmission.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended ~~March 31,~~June 30, 2022 were ~~$25.9~~$27.1 million compared to ~~$22.7~~$26.2 million for the same period in 2021. The increase in selling, general and administrative expenses was primarily due toan increase in travel and in-person events including more physician engagement and educational programs in addition to higher depreciation related to the new office space in Cambridge, Massachusetts.

Selling, general and administrative expenses for the six months ended June 30, 2022 were $53.0 million compared to $48.9 million for the same period in 2021. The increase in selling, general and administrative expenses was primarily due to an increase of ~~$1.8~~$1.7 million in stock-based compensation expenses, an increase in travel and in-person events including more physician engagement and educational programs in addition to ~~an increase~~higher depreciation related to the new office space in ~~professional services, employee related expenses and depreciation.~~Cambridge, Massachusetts.

Total Other Income (Expense)

The change in other income (expense) for the three and six months ended ~~March 31,~~June 30, 2022, compared to the same ~~period~~periods in 2021 was due primarily to fluctuations in the rates of return on our investments in various marketable debt securities.

Income Tax Expense

~~For the three months ended March 31, 2021~~No income tax expense ~~of $0.1 million~~ was recorded ~~and no expense for income taxes was recognized~~ for the ~~same period in 2022.~~three and six months ended June 30, 2022, compared to $0.1 million and $0.2 million recorded for the three and six months ended June 30, 2021, respectively.

Table of Contents

Stock-Based Compensation Expense

Non-cash stock-based compensation expense is summarized in the following table:


		Three Months Ended March 31,								Three Months Ended June 30,								Six Months Ended June 30,
(In thousands)	(In thousands)	2022		2021		Change $		Change %			(In thousands)	2022		2021		Change $		Change %		2022		2021		Change $		Change %
Cost of product sales	Cost of product sales	$	1,118	$	911	$	207	22.7	%		Cost of product sales	$	1,035	$	1,287	$	(252)	(19.6)	%	$	2,153	$	2,199	$	(46)	(2.1)	%
Research and development	Research and development	1,350		863		487		56.4	%		Research and development	1,520		1,234		286		23.2	%	2,870		2,096		774		36.9	%
Selling, general and administrative	Selling, general and administrative	7,063		5,245		1,818		34.7	%		Selling, general and administrative	8,253		8,345		(92)		(1.1)	%	15,316		13,590		1,726		12.7	%
Total non-cash stock-based compensation expense	Total non-cash stock-based compensation expense	$	9,531	$	7,019	$	2,512	35.8	%		Total non-cash stock-based compensation expense	$	10,808	$	10,866	$	(58)	(0.5)	%	$	20,339	$	17,885	$	2,454	13.7	%

The increase in stock-based compensation expense for the ~~three~~six months ended ~~March 31,~~June 30, 2022 compared to the same period in 2021, was due primarily to fluctuations in stock prices which impact the fair value of the options and restricted stock units awarded and the expense recognized in the period.

Liquidity and Capital Resources

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:


	Six Months Ended June 30,
(In thousands)	2022		2021
Net cash provided by operating activities	$	6,611	$	14,855
Net cash used in investing activities	(13,666)		(2,757)
Net cash provided by financing activities	752		6,043
Net (decrease) increase in cash, cash equivalents, and restricted cash	$	(6,303)	$	18,141

Net Cash Provided by Operating Activities

Our cash, cash equivalents and restricted cash totaled $62.2 million, short-term investments totaled $44.6 million and long-term investments totaled $23.7 million as of June 30, 2022. The $6.6 million of cash provided by operations during the six months ended June 30, 2022 was primarily the result of non-cash charges of $20.3 million related to stock-based compensation expense, $2.2 million of operating lease amortization and $1.9 million in depreciation and amortization expense, offset by a net loss of $16.1 million and a net decrease of $2.1 million related to movements in our working capital accounts. The overall decrease in cash from our working capital accounts was primarily driven by a decrease in accrued expenses due to timing of payments, a decrease in operating lease liabilities, an increase in inventory due to increased production needs, offset by a decrease in accounts receivable due to cash collections.

Our cash, cash equivalents and restricted cash totaled $52.0 million, short-term investments totaled $39.2 million and long-term investments totaled $24.8 million as of June 30, 2021. The $14.9 million of cash provided by operations during the six months ended June 30, 2021 was primarily the result of non-cash charges of $17.9 million related to stock compensation expense, $2.3 million of operating lease amortization, and $1.5 million in depreciation and amortization expense, offset by a net loss of $7.1 million, and a net decrease of $0.3 million related to movements in our working capital accounts. The overall decrease in cash from our working capital accounts was primarily driven by a decrease in accounts receivable due to a decrease in sales volume compared to the previous sequential quarter, an increase in inventory due to increased production needs, and an increase in operating lease liabilities.

Net Cash Used In by Investing Activities

Net cash used in investing activities during the six months ended June 30, 2022 was the result of $34.9 million in investment purchases and $5.1 million of property and equipment purchases primarily for manufacturing upgrades and leasehold improvements, offset by $26.3 million of investment sales and maturities.

Table of Contents

Net cash used in investing activities during the six months ended June 30, 2021 was the result of $31.0 million in investments purchases and equipment purchases of $4.5 million, primarily for manufacturing upgrades and leasehold improvements, offset by $32.7 million of investment sales and maturities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities during the six months ended June 30, 2022 was the result of net proceeds from the exercise of stock options and the employee stock purchase plan of $2.2 million partially offset by payments of employee withholding taxes related to the vesting of restricted stock units of $1.4 million.

Net cash provided by financing activities during the six months ended June 30, 2021 was primarily the result of net proceeds from the exercise of stock options of $7.6 million, partially offset by the payment of employee withholding taxes related to the vesting of restricted stock units of $1.6 million.

Liquidity

Since our acquisition of MACI and Epicel in 2014, our primary focus has been to invest in our existing commercial business with the goal of growing revenue. We have raised significant funds in order to complete our product development programs and to market and commercialize our products, including NexoBrid. To date, we have financed our operations primarily through cash received through Epicel and MACI sales, debt and public and private sales of our equity securities. We generated ~~$3.5~~$6.6 million in operating cash flows during the ~~three~~six months ended ~~March 31,~~June 30, 2022, and we may finance our operations through the sales of equity securities or debt financings.

We believe that our current cash on hand, cash equivalents investments, and ~~investments~~borrowing capacity will be sufficient to support our current operations through at least 12 months from the issuance of these condensed consolidated financial statements. However, the continuing effects of the ongoing COVID-19 pandemic continue to evolve and may adversely impact our business and operations. Our actual cash requirements may differ from projections and will depend on many factors, including any future impacts of the COVID-19 pandemic, the level of future research and development, the scope and results of ongoing and potential clinical trials, the costs involved in filing, prosecuting and enforcing patents, the need for additional manufacturing capacity, competing technological and market developments, costs of possible acquisition or development of complementary business activities, and the cost to market our products.

~~At March 31,~~As of June 30, 2022, we were not party to any off-balance sheet arrangements.

~~Table of Contents~~

~~Cash Flows~~

~~The following table summarizes our sources and uses of cash for each of the periods presented:~~

Three months ended March 31,
(In thousands) 2022 2021
Net cash provided by operating activities $ 3,468 $ 10,086
Net cash (used in) provided by investing activities (10,669) 12,186
Net cash provided by financing activities 503 2,262
Net (decrease) increase in cash, cash equivalents, and restricted cash $ (6,698) $ 24,534

~~Net Cash Provided by Operating Activities~~

Our cash, cash equivalents and restricted cash totaled $61.8 million, short-term investments totaled $44.9 million and long-term investments totaled $22.8 million as of March 31, 2022. The $3.5 million of cash provided by operations during the three months ended March 31, 2022 was primarily the result of non-cash charges of $9.5 million related to stock-based compensation expense, $1.1 million of operating lease amortization and $0.9 million in depreciation and amortization expense, offset by a net loss of $7.1 million and a net decrease of $1.1 million related to movements in our working capital accounts. The overall decrease in cash from our working capital accounts was primarily driven by a decrease in accounts payable and accrued expenses due to timing of payments, an increase in inventory due to increased production needs, offset by a decrease in accounts receivable due to a decrease in sales volume compared to the previous sequential quarter.

Our cash, cash equivalents and restricted cash totaled $58.4 million, short-term investments totaled $25.4 million and long-term investments totaled $26.0 million as of March 31, 2021. The $10.1 million of cash provided by operations during the three months ended March 31, 2021 was primarily the result of non-cash charges of $7.0 million related to stock-based compensation expense, $1.2 million of operating lease amortization, $0.8 million in depreciation and amortization expense, offset by a net loss of $3.3 million and a net increase of $4.1 million related to movements in our working capital accounts. The overall increase in cash from our working capital accounts was primarily driven by an decrease in accounts receivable due to a decrease in sales volume compared to the previous sequential quarter, a net increase of accounts payable and accrued expenses due to timing of payments and a decrease in inventory due to decreased production needs.

~~Net Cash (Used In) Provided by Investing Activities~~

Net cash used in investing activities during the three months ended March 31, 2022 was the result of $12.6 million in investment purchases and $3.1 million of property and equipment purchases primarily for manufacturing upgrades and leasehold improvements, offset by $5.0 million of investment sales and maturities.

Net cash provided by investing activities during the three months ended March 31, 2021 was the result of $25.0 million of investment sales and maturities, offset by $10.4 million in investments purchases and equipment purchases of $2.3 million, primarily for manufacturing upgrades and leasehold improvements.

~~Net Cash Provided by Financing Activities~~

Net cash provided by financing activities during the three months ended March 31, 2022 was the result of net proceeds from the exercise of stock options and the employee stock purchase plan of $1.5 million partially offset by payments of employee withholding taxes related to the vesting of restricted stock units of $0.9 million.

Net cash provided by financing activities during the three months ended March 31, 2021 was primarily the result of net proceeds from the exercise of stock options of $3.8 million, partially offset by the payment of employee withholding taxes related to the vesting of restricted stock units of $1.5 million.

Sources of Capital

On August 27, 2021, we entered into a Sales Agreement with SVB Leerink LLC, as sales agent (“SVB Leerink”), pursuant to which we may offer and sell up to $200.0 million of shares of our common stock, no par value per share (“ATM Shares”). The ATM Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to an automatically effective shelf registration statement on Form S-3ASR (File No. 333-259119) filed by us on August 27, 2021, which expires

~~Table of Contents~~

three years from the filing date. We also filed a prospectus supplement relating to the offering and sale of the ATM Shares on August 27, 2021. We are not obligated to make any sales of ATM Shares, and SVB Leerink is not required to sell any specific number or dollar amount of the ATM Shares under the Sales Agreement. As of ~~March 31,~~June 30, 2022, we have sold no shares pursuant to the Sales Agreement.

~~If revenue declines~~On July 29, 2022, we entered into a $150 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). We have no immediate plans to borrow under the Revolving Credit Agreement, but we will use the facility for a sustained period, we may need to access additional capital; however, we may not be able to obtain financing on acceptable terms or at all. Market volatility could also adversely impact our ability to access financing when needed. The terms of any financing may adversely affect the holdings or the rights of our shareholders. Actual cash requirements may differ from projectionsworking capital needs and ~~will depend on many factors, including any future impacts~~other general corporate purposes, as desired. As of the ~~COVID-19 pandemic,~~filing of this Quarterly Report on Form 10-Q, there are no outstanding borrowings under the ~~level~~Revolving Credit Agreement, and we are in compliance with all covenant requirements of ~~future research and development,~~ the ~~scope and results of ongoing and potential clinical trials,~~Revolving Credit Agreement. See Note 12, “Subsequent Events” in the costs involved in filing, prosecuting and enforcing patents, the need for additional manufacturing capacity, competing technological and market developments, costs of possible acquisition or development of complementary business activities, and the cost to market our products.accompanying condensed consolidated financial statements.

Table of Contents

Contractual Obligations and Commitments

The disclosure of our contractual obligations and commitments is set forth in the heading “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes, outside of the ordinary course of business, to our contractual obligations and commitments since December 31, 2021, except as discussed in Note 5, “Leases” in the accompanying condensed consolidated financial statements.

Table of Contents

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, expenses, and related disclosures. Actual results may differ materially from these estimates under different assumptions and conditions.

There have been no material changes to our critical accounting policies and estimates in the ~~three~~six months ended ~~March 31,~~June 30, 2022. For further information, refer to our summary of significant accounting policies and estimates in our Annual Report on Form 10-K filed for the year ended December 31, 2021.

Cautionary Note Regarding Forward-Looking Statements

This report, including the documents incorporated by reference herein, contains certain statements that describe our management’s beliefs concerning future business conditions, plans and prospects, growth opportunities and the outlook for our business based upon information currently available. Such statements are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Wherever possible, we have identified these forward-looking statements by words such as “will,” “may,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “projects,” “trends,” “opportunity,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “target,” “achieve,” “continuing,” “ongoing,” and similar words or phrases, or future or conditional verbs such as “would,” “should,” “could,” “may,” or similar expressions. These forward-looking statements are based upon assumptions our management believes are reasonable. Such forward-looking statements are subject to risks and uncertainties which could cause our actual results, performance and achievements to differ materially from those expressed in, or implied by, these statements, including, among others, the risks and uncertainties listed in our Annual Report under “Part I, Item 1A Risk Factors.”

Because our forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different and any or all of our forward-looking statements may turn out to be wrong. Forward-looking statements speak only as of the date made and can be affected by assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in our Annual Report will be important in determining future results. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. Consequently, we cannot assure you that our expectations or forecasts expressed in such forward-looking statements will be achieved. Except as required

~~Table of Contents~~

by law, we undertake no obligation to publicly update any of our forward-looking or other statements, whether as a result of new information, future events, or otherwise. These forward-looking statements include statements regarding:

•manufacturing and facility capabilities;

•potential strategic collaborations with others;

•future capital needs and financing sources;

•adequacy of existing capital to support operations for a specified time;

•reimbursement for our products;

•the timing of ~~a response to the FDA’s complete response letter regarding the NexoBrid BLA;~~

•~~the timing of~~ the FDA’s review of ~~any resubmission of~~ the NexoBrid ~~BLA;~~BLA resubmission;

•expectations regarding approval by the FDA of the NexoBrid BLA;

•product development and marketing plans;

•features and successes of our therapies;

•clinical trial plans, including publication thereof;

•the effects of the ongoing COVID-19 pandemic on our business, including economic slowdowns or recessions, impact to our operations or to the healthcare industry generally, which could reduce demand for our products;

•anticipated inflationary pressures and our responses thereto as well as other unfavorable global and regional economic conditions, geopolitical events, and military conflicts, such as repercussions from the recent conflict in Ukraine;

•anticipation of future losses;

•replacement of manufacturing sources;

•commercialization plans; or

•revenue expectations and operating results.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

For quantitative and qualitative disclosures about market risk, see Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2021. Our exposures to market risk have not changed materially since December 31, 2021.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its Certifying Officers), evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation as of ~~March 31,~~June 30, 2022, the Company’s Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities and Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management of the Company, with the participation of its Certifying Officers, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the three months ended ~~March 31,~~June 30, 2022, there were no material changes made in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act).

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not party to any material legal proceedings, although from time to time we may become involved in disputes in connection with the operation of our business.

Item 1A. Risk Factors

Factors that could cause the Company’s actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on the 10-K for the fiscal year ended December 31, 2021 filed with the SEC on February 24, 2022. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on the 10-K for the fiscal year ended December 31, 2021, except as follows.

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, an ongoing military conflict between Russia and Ukraine, and record inflation. Our business, financial condition and results of operations could be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine, geopolitical tensions, or record inflation.

U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. In February 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to record inflation globally. We are continuing to monitor inflation, the situation in Ukraine and global capital markets and assessing its potential impact on our business.

Table of Contents

~~There have~~Although, to date, our business has not been ~~no material changes from~~materially impacted by the ~~risk factors previously disclosed~~ongoing military conflict between Russian and Ukraine, geopolitical tensions, or record inflation, it is impossible to predict the extent to which our operations will be impacted in the ~~Company's Annual Report on Form 10-K for~~short and long term, or the ~~year ended December 31, 2021.~~ways in which such matters may impact our business. The extent and duration of the conflict in Ukraine, geopolitical tensions, record inflation and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks described in the ~~Annual Report~~10-K.

NexoBrid’s approval in the U.S. for the treatment of severe burns may be further delayed, or it may not be approved by the FDA for use in the U.S. at all.

On June 29, 2021, we announced that MediWound had received a CRL from the FDA with respect to a BLA that MediWound had previously submitted to the FDA seeking marketing approval for NexoBrid in the U.S. As part of the CRL, the FDA communicated to MediWound that it had completed its review of the BLA, as amended, and had determined that it could not approve the BLA in its then form. The FDA identified issues related to the chemistry, manufacturing and controls, or CMC section of the BLA and had requested that MediWound provide additional CMC information. The FDA stated that it had not reviewed several amendments submitted by MediWound in response to the CMC information requests related to the BLA. The FDA also stated that inspections of manufacturing facilities in Israel and Taiwan are required before the BLA can be approved, but that it was unable to conduct the required inspections during the original review cycle due to COVID-19-related travel restrictions. In addition, the CRL referenced observations that were made during GCP inspections related to the Phase 3 pivotal DETECT study and requested that MediWound address questions regarding the impact of the observations on ~~Form 10-K are not~~ the ~~only risks~~study’s efficacy findings. The FDA also requested that MediWound provide a safety update as part of a BLA resubmission.

We have continued to work with MediWound, BARDA and the ~~Company faces. Additional risks~~FDA to address the issues identified in the CRL, and ~~uncertainties not currently known~~on July 1, 2022, Vericel and MediWound submitted a BLA resubmission to the FDA to address the issues identified by the FDA in the CRL. Subsequently, the FDA informed us that it has accepted the resubmission for review and has established a PDUFA date for completing that review of January 1, 2023. We cannot predict the likelihood that the FDA will ultimately approve the NexoBrid BLA. We also cannot predict whether current geopolitical tensions between the U.S. and China will affect or ~~currently deemed~~delay the FDA’s ability to conduct inspections of the NexoBrid manufacturing facility located in Taiwan. In addition, if approval to market NexoBrid is sought in Mexico or Canada, we cannot predict how long regulatory authorities in those countries will take to provide NexoBrid with marketing authorization in their jurisdictions or whether such authorizations will be ~~immaterial also~~granted at all. A significant delay or a failure to receive regulatory approval for NexoBrid in the U.S. may ~~materially and adversely affect the Company’s~~have a material adverse impact on our business ~~financial condition, results of operations or cash flows.~~prospects.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

2730

Table of Contents

Item 6. Exhibits

The Exhibits listed in the Exhibit Index are filed as a part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX


Exhibit No.						Description

3.1						Restated Articles of Incorporation of the Company, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 17, 2009, incorporated herein by reference.

3.2						Certificate of Amendment to Restated Articles of Incorporation of the Company, dated February 9, 2010, filed as Exhibit 3.2 to the Company’s Post-Effective Amendment No. 1 to Form S-1 filed on March 31, 2010, incorporated herein by reference.

3.3						Certificate of Amendment to Restated Articles of Incorporation of the Company, dated March 22, 2011, attached as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 25, 2011, incorporated herein by reference.

3.4						Certificate of Amendment to the Restated Articles of Incorporation of the Company, dated November 21, 2014, attached as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on November 24, 2014, incorporated herein by reference.

3.5						Bylaws, as amended, attached as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on November 12, 2010, incorporated herein by reference.

~~10.1*†~~10.1†						Lease Agreement, dated January 28, 2022, by and between the Company and NBD Property Owner 2, L.P., (incorporated herein by reference to Exhibit 10.1 on form 10-Q filed May 4, 2022).

10.2*10.2						Form of Current Employee Incentive Stock Option Agreement under the 2019 Omnibus Incentive Plan, ~~(amended~~amended February 15, 2022, (incorporated herein by reference to exhibit 10.1 on form 10-Q filed May 4, 2022).

10.3*10.3						Form of New Hire Incentive Stock Option Award Agreement under the 2019 Omnibus Incentive Plan ~~(amended~~amended February 15, 2022, (incorporated herein by reference to exhibit 10.1 on form 10-Q filed May 4, 2022).

10.4*10.4						Form of Non-Qualified Stock Option Award Agreement for Non-Employee Directors under the 2019 Omnibus Incentive Plan ~~(amended~~amended February 15, 2022, (incorporated herein by reference to exhibit 10.1 on form 10-Q filed May 4, 2022).

10.5*						Eighth Amendment to the Distribution Agreement between Orsini Pharmaceutical Services, Inc. and the Company, dated May 15, 2022.

10.6*						Third Amendment to the Dispensing Agreement between AllCare Plus Pharmacy, Inc. and the Company, dated May 16, 2022.

10.7*						Form of New Hire Incentive Stock Option Agreement under the 2022 Omnibus Incentive Plan (effective April 26 , 2022).

10.8*						Form of Current Employee Incentive Stock Option Agreement under the 2022 Omnibus Incentive Plan (effective April 26 , 2022).

10.9*						Form of Restricted Stock Unit Award Agreement for Employees under the 2022 Omnibus Incentive Plan (effecti ve April 26 , 2022).

10.10*						Form of Restricted Stock Unit Award Agreement for Non-employee Directors under the 2022 Omnibus Incentive Plan (effective April 26 , 2022).

10.11*						Form of Non-Qualified Stock Option Award Agreement for Non-Employee Directors under the 2022 Omnibus Incentive Plan (effective April 26 , 2022).

31.1*						Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Table of Contents


Exhibit No.						Description
31.2*						Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*						Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*						Inline XBRL Instance Document

101.SCH*						Inline XBRL Taxonomy Extension Schema Document

101.CAL*						Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB*						Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*						Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF*						Inline XBRL Taxonomy Extension Definition Linkbase Document

104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

~~Table of Contents~~

~~# Management contract or compensatory plan or arrangement covering executive officers or directors of Vericel.~~

* Filed herewith.

† Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

2932

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: ~~May 4,~~August 3, 2022


			VERICEL CORPORATION


			/s/ DOMINICK C. COLANGELO
			Dominick C. Colangelo
			President and Chief Executive Officer
			(Principal Executive Officer)


			/s/ JOSEPH A. MARA
			Joseph A. Mara
			Chief Financial Officer
			(Principal Financial Officer)

3033